Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice

Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice

Background. Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current approaches have greatly improved patients outcomes, but relapse is inevitable. In phase IIIII clinical trials, ibrutinib has shown significant activity in patients with relapsed or refractory (R/R) M...

Full description

Bibliographic Details
Main Authors: Vladimir I. Vorobyev, Eduard G. Gemdzhian, Liudmila V. Fedorova, Natalia B. Mikhailova, Ridvan K. Ilyasov, Liliia P. Kaleikina, Olga S. Trubyakova, Kamil D. Kaplanov, Elena V. Melnichenko, Elena V. Martynova, Elena P. Yakovleva, Olga Yu. Li, Elena V. Tarasenko, Elena P. Chumakova, Natalia B. Bulieva, Ekaterina S. Nesterova, Oleg V. Margolin, Vera A. Zherebtsova, Lev S. Butaev, Vadim V. Ptushkin
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2021-07-01
Series:Терапевтический архив
Subjects:
ibrutinib
mantle cell lymphoma
real-world practice
refractory
relapsed
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/76311/56902

Internet

https://ter-arkhiv.ru/0040-3660/article/viewFile/76311/56902

Similar Items